Great Point Partners as of March 31, 2023
Portfolio Holdings for Great Point Partners
Great Point Partners holds 42 positions in its portfolio as reported in the March 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Pliant Therapeutics (PLRX) | 6.3 | $32M | 1.2M | 26.60 | |
| Xenon Pharmaceuticals (XENE) | 5.8 | $29M | 819k | 35.79 | |
| Alpine Immune Sciences (ALPN) | 5.7 | $29M | 3.7M | 7.72 | |
| Ultragenyx Pharmaceutical (RARE) | 5.3 | $27M | 677k | 40.10 | |
| Rapt Therapeutics (RAPT) | 4.9 | $25M | 1.4M | 18.35 | |
| Vaxcyte (PCVX) | 4.9 | $25M | 659k | 37.48 | |
| Point Biopharma Global | 4.8 | $25M | 3.4M | 7.27 | |
| Amylyx Pharmaceuticals (AMLX) | 4.5 | $23M | 784k | 29.34 | |
| Travere Therapeutics (TVTX) | 4.4 | $23M | 1.0M | 22.49 | |
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 4.3 | $22M | 150k | 146.33 | |
| Evolus (EOLS) | 3.6 | $19M | 2.2M | 8.46 | |
| Viking Therapeutics (VKTX) | 3.5 | $18M | 1.1M | 16.65 | |
| Cytokinetics Com New (CYTK) | 3.5 | $18M | 500k | 35.19 | |
| Anaptysbio Inc Common (ANAB) | 3.4 | $18M | 804k | 21.76 | |
| Iveric Bio | 3.3 | $17M | 694k | 24.33 | |
| Aerovate Therapeutics (AVTE) | 3.0 | $15M | 756k | 20.17 | |
| Optinose (OPTN) | 3.0 | $15M | 7.9M | 1.93 | |
| Immunocore Hldgs Ads (IMCR) | 2.5 | $13M | 255k | 49.44 | |
| Kalvista Pharmaceuticals (KALV) | 2.5 | $13M | 1.6M | 7.86 | |
| Aclaris Therapeutics Call Option (ACRS) | 2.3 | $12M | 1.4M | 8.09 | |
| Relay Therapeutics (RLAY) | 2.1 | $11M | 658k | 16.47 | |
| Mineralys Therapeutics (MLYS) | 1.9 | $9.7M | 620k | 15.66 | |
| Heron Therapeutics (HRTX) | 1.7 | $8.8M | 5.8M | 1.51 | |
| Arcellx Common Stock (ACLX) | 1.6 | $7.9M | 257k | 30.81 | |
| Precision Biosciences Ord | 1.2 | $6.1M | 8.1M | 0.75 | |
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.2 | $6.0M | 278k | 21.39 | |
| Gracell Biotechnologies Sponsored Ads | 1.2 | $5.9M | 3.2M | 1.86 | |
| Cymabay Therapeutics | 0.9 | $4.4M | 508k | 8.72 | |
| Generation Bio (GBIO) | 0.9 | $4.4M | 1.0M | 4.30 | |
| Acumen Pharmaceuticals (ABOS) | 0.8 | $4.3M | 1.1M | 4.06 | |
| Amicus Therapeutics (FOLD) | 0.8 | $4.2M | 380k | 11.09 | |
| Larimar Therapeutics (LRMR) | 0.8 | $4.1M | 900k | 4.53 | |
| Intra Cellular Therapies (ITCI) | 0.7 | $3.8M | 70k | 54.15 | |
| 89bio (ETNB) | 0.7 | $3.8M | 250k | 15.23 | |
| Zevra Therapeutics Com New (ZVRA) | 0.4 | $1.9M | 348k | 5.50 | |
| Day One Biopharmaceuticals I (DAWN) | 0.4 | $1.9M | 142k | 13.37 | |
| Rhythm Pharmaceuticals (RYTM) | 0.3 | $1.7M | 98k | 17.84 | |
| Praxis Precision Medicines I | 0.3 | $1.6M | 2.0M | 0.81 | |
| Solid Biosciences Com New (SLDB) | 0.2 | $997k | 210k | 4.74 | |
| Avalo Therapeutics Com New | 0.2 | $831k | 475k | 1.75 | |
| Reneo Pharmaceuticals (RPHM) | 0.1 | $723k | 121k | 5.98 | |
| Urogen Pharma (URGN) | 0.1 | $362k | 39k | 9.24 |
